Eledon Pharmaceuticals, Inc. — Director's Dealing 2017

May 26, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Novus Therapeutics, Inc. (NVUS)
CIK: 0001404281
Period of Report: 2017-05-24

Reporting Person: FLESHER GREGORY J. (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-24	Stock Option (Right to Buy)	$5.50	A	250000	Acquired	2027-05-23	Common Stock (250000)	Direct

Footnotes

F1: This option represents a right to purchase a total of 250,000 shares of the Issuer's Common Stock. 150,000 shares will vest ratably each month over three years beginning on May 24, 2017 (the "grant date"). 100,000 shares will vest on the later of achievement of a performance-related goal or the first anniversary of the grant date.